Viking Therapeutics (VKTX) Free Cash Flow (2014 - 2026)

Viking Therapeutics has reported Free Cash Flow for 13 years, with the latest figure at -$125.2 million in Q2 2026.

• Quarterly Free Cash Flow fell 165.98% year-over-year to -$125.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$418.4 million (down 174.32% YoY) and the FY2025 annual result came in at -$278.7 million, down 217.45% from the prior year.
• Free Cash Flow eased to -$125.2 million in Q2 2026 per VKTX's latest filing, from -$114.0 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$6.1 million in Q1 2024 and troughed at -$125.2 million in Q2 2026.
• A 5-year average of -$40.4 million and a median of -$23.3 million in 2023 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2024 and 2025: Free Cash Flow surged 75.11% in 2024, then plunged 753.13% in 2025.
• Over 5 years, Free Cash Flow stood at -$10.9 million in 2022, then sank by 61.45% to -$17.6 million in 2023, then slumped by 76.76% to -$31.2 million in 2024, then plunged by 173.53% to -$85.3 million in 2025, then sank by 46.76% to -$125.2 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$125.2 million, -$114.0 million, and -$85.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.